Back to Browse Journals » Vascular Health and Risk Management » Volume 4 » Issue 3

Antiplatelet drugs in cardiological practice: Established strategies and new developments

Authors Florian Krötz, Hae-Young Sohn, Volker Klauss

Published 6 June 2008 Volume 2008:4(3) Pages 637—645


Florian Krötz, Hae-Young Sohn, Volker Klauss

Cardiology, Medical Policlinic, Ludwig-Maximilians-Universität, Ziemssenstr. 1, 80336 München

Abstract: A common pathophysiological course in vascular diseases is an overwhelming activation and aggregation of blood platelets, which results in atherothrombosis. By causing the last decisive step of cerebral, coronary, or peripheral arterial ischemia thrombotic complications of atherosclerotic disease represent a major player in death cause statistics of most western countries. The development of novel therapies against platelet-dependent thrombosis and the concurrent improvement of existing therapeutic strategies thus is a paramount focus of pharmaceutical research. Currently, efficiency, dosing and indications of established antiplatelet substances are being re-evaluated, whilst new, so far unrecognized molecular targets for inhibition of platelet activity come up front. This not only allows for interesting new therapeutical options, but also widens our insight into the role platelets play in atherosclerosis in general. This article summarizes the relevant pathophysiology of platelet activation, presents current concepts in antiplatelet drug therapy, and highlights the role of platelets in vascular diseases apart from atherothrombosis.

Keywords: atherothrombosis, antiplatelet drug therapy, pathophysiology, platelet activation

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Argatroban in the management of heparin-induced thrombocytopenia

Luciano Babuin, Vittorio Pengo

Vascular Health and Risk Management 2010, 6:813-819

Published Date: 1 September 2010

Current and emerging therapeutic options for the treatment of chronic chagasic cardiomyopathy

Claudio A Muratore, Adrian Baranchuk

Vascular Health and Risk Management 2010, 6:593-601

Published Date: 14 July 2010

Mitigating micro- and macro-vascular complications of diabetes beginning in adolescence

Daniel J Moore, Justin M Gregory, Yaa A Kumah-Crystal, et al

Vascular Health and Risk Management 2009, 5:1015-1031

Published Date: 18 November 2009

Cardiovascular disease in patients with chronic kidney disease

Julian Wright, Alastair Hutchison

Vascular Health and Risk Management 2009, 5:713-722

Published Date: 26 August 2009

Cardiovascular co-morbidity in rheumatic diseases

Carl Turesson, Lennart TH Jacobsson, Eric L Matteson

Vascular Health and Risk Management 2008, 4:605-614

Published Date: 6 June 2008

Clinical trial update: focus on the ONTARGET study

David Fitchett

Vascular Health and Risk Management 2007, 3:901-908

Published Date: 15 January 2008

Bisoprolol in the treatment of chronic heart failure

Pascal de Groote, Pierre-Vladimir Ennezat, Fréderic Mouquet

Vascular Health and Risk Management 2007, 3:431-439

Published Date: 15 September 2007

Metabolic syndrome, inflammation and atherosclerosis

Rodolfo Paoletti, Chiara Bolego, Andrea Poli, Andrea Cignarella

Vascular Health and Risk Management 2006, 2:145-152

Published Date: 15 June 2006